BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 9815658)

  • 1. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor.
    Shimamura R; Fraizer GC; Trapman J; Lau YfC ; Saunders GF
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2571-80. PubMed ID: 9815658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Wilms tumor 1 (WT1) in the transcriptional regulation of the Mullerian-inhibiting substance promoter.
    Hossain A; Saunders GF
    Biol Reprod; 2003 Dec; 69(6):1808-14. PubMed ID: 12855602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A; Fraizer GC; Piantanelli L; Saunders GF
    Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wilms tumor and the WT1 gene.
    Lee SB; Haber DA
    Exp Cell Res; 2001 Mar; 264(1):74-99. PubMed ID: 11237525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of Wilms' tumor genes.
    Hirose M
    J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.
    Menke AL; Riteco N; van Ham RC; de Bruyne C; Rauscher FJ; van der Eb AJ; Jochemsen AG
    Oncogene; 1996 Feb; 12(3):537-46. PubMed ID: 8637710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1.
    Cook DM; Hinkes MT; Bernfield M; Rauscher FJ
    Oncogene; 1996 Oct; 13(8):1789-99. PubMed ID: 8895526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of ovine SRY transcript and developmental expression of genes involved in sexual differentiation.
    Payen E; Pailhoux E; Abou Merhi R; Gianquinto L; Kirszenbaum M; Locatelli A; Cotinot C
    Int J Dev Biol; 1996 Jun; 40(3):567-75. PubMed ID: 8840189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
    Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
    Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways.
    Wang ZY; Qiu QQ; Huang J; Gurrieri M; Deuel TF
    Oncogene; 1995 Feb; 10(3):415-22. PubMed ID: 7845666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional properties of WT1.
    Haber DA; Englert C; Maheswaran S
    Med Pediatr Oncol; 1996 Nov; 27(5):453-5. PubMed ID: 8827073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1.
    Zhang X; Xing G; Saunders GF
    Anticancer Res; 1999; 19(3A):1641-8. PubMed ID: 10470095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wilms' tumor protein Wt1 is an activator of the anti-Müllerian hormone receptor gene Amhr2.
    Klattig J; Sierig R; Kruspe D; Besenbeck B; Englert C
    Mol Cell Biol; 2007 Jun; 27(12):4355-64. PubMed ID: 17420277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cell-autonomous role for WT1 in regulating Sry in vivo.
    Bradford ST; Wilhelm D; Bandiera R; Vidal V; Schedl A; Koopman P
    Hum Mol Genet; 2009 Sep; 18(18):3429-38. PubMed ID: 19549635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wilms' tumor suppressor gene (WT1) as a target gene of SRY function in a mouse ES cell line transfected with SRY.
    Toyooka Y; Tanaka SS; Hirota O; Tanaka S; Takagi N; Yamanouchi K; Tojo H; Tachi C
    Int J Dev Biol; 1998 Nov; 42(8):1143-51. PubMed ID: 9879712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imbalanced expression of functionally different WT1 isoforms may contribute to sporadic unilateral Wilms' tumor.
    Liu JJ; Wang ZY; Deuel TF; Xu YH
    Biochem Biophys Res Commun; 1999 Jan; 254(1):197-9. PubMed ID: 9920757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
    Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
    Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wilms' tumor 1-KTS isoforms induce p53-independent apoptosis that can be partially rescued by expression of the epidermal growth factor receptor or the insulin receptor.
    Menke AL; Shvarts A; Riteco N; van Ham RC; van der Eb AJ; Jochemsen AG
    Cancer Res; 1997 Apr; 57(7):1353-63. PubMed ID: 9102224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the Wilms' tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in C.B-17 scid/scid mice.
    Smith SI; Down M; Boyd AW; Li CL
    Cancer Res; 2000 Feb; 60(4):808-14. PubMed ID: 10706085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of native WT1 protein from frozen human kidney and Wilms' tumors.
    Iben S; Royer-Pokora B
    Oncogene; 1999 Apr; 18(15):2533-6. PubMed ID: 10229205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.